stockrow
Friday 6 November 2026
Export SUPN’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
26.00
0.74
−2.77%
Follow SUPN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
9.66 | 14.20 | 15.09 | 21.23 |
+8 more quarters Free account |
P/S ratio |
3.08 | 3.67 | 2.93 | 3.62 | |
P/FCF ratio |
145.87 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
43.61 | 21.32 | (419.95) | (20.29) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.57 | 3.89 | 3.19 | 3.72 | |
EV/EBITDA |
8.58 | 11.85 | 11.74 | 16.34 | |
EV/Operating CF |
51.04 | (129.41) | (37.11) | (170.70) | |
EV/FCF |
168.98 | (45.81) | (21.23) | (48.52) | |
Quick Ratio |
0.45 | 0.59 | 0.59 | 0.49 | |
Current Ratio |
0.61 | 0.84 | 0.86 | 0.71 | |
Net Debt/EBITDA |
1.00 | 1.64 | 2.21 | 1.46 | |
Debt/Assets |
36.64% | 39.50% | 40.60% | 26.56% | |
Debt/Equity |
(8.13) | (2.34) | (3.37) | (3.26) | |
Asset Turnover |
1.00 | 0.99 | 1.00 | 0.98 | |
Operating CF/Net income |
0.71 | 1.88 | (0.10) | (2.15) | |
Capex/Depreciation |
(7.00) | (2.33) | (5.00) | (4.80) | |
Interest Coverage |
90.50 | 79.50 | 19.57 | 13.33 | |
Research and Development Expense of Revenue |
1.40% | 3.50% | 5.05% | 5.88% | |
Selling, General and Administrative Expense of Revenue |
33.43% | 35.57% | 39.12% | 52.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.25% | 3.21% | 2.84% | 1.40% | |
Graham Net Nets |
(0.14) | (0.15) | (0.18) | (0.14) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
10.35% | 7.04% | 6.63% | 4.71% | |
Free Cash Flow Yield |
0.69% | (2.31%) | (5.13%) | (2.12%) | |
Revenue per Share |
3.02 | 2.88 | 2.56 | 2.86 | |
Operating CF per Share |
0.82 | 1.92 | (0.07) | (1.77) | |
Capex per Share |
(0.12) | (0.06) | (0.16) | (0.19) | |
Free Cash Flow per Share |
0.70 | 1.87 | (0.23) | (1.96) | |
Cash per Share |
2.58 | 1.87 | 1.41 | 1.56 | |
Shareholders Equity per Share |
(0.51) | (1.75) | (1.16) | (0.78) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.51) | (1.75) | (1.16) | (0.78) | |
Free Cash Flow |
83.00 | 222.00 | (29.00) | (245.00) | |
Working Capital |
(501.00) | (143.00) | (112.00) | (262.00) | |
Capital Expenditures |
(14.00) | (7.00) | (20.00) | (24.00) | |
Net Current Asset Value |
(592.00) | (716.00) | (674.00) | (648.00) | |
EV/EBIT |
8.80 | 12.33 | 12.41 | 17.59 | |
Capex to Sales |
0.04 | 0.02 | 0.06 | 0.07 | |
Price to Operating Income |
7.59 | 11.63 | 11.38 | 17.12 | |
| Other line items | |||||
Average Receivables |
279.00 | 265.00 | 278.50 | 271.00 | |
Average Payables |
198.00 | 201.00 | 180.50 | 233.00 | |
Average Inventory |
152.00 | 149.50 | 157.50 | 160.00 | |
Average Assets |
1,374.00 | 1,342.50 | 1,286.00 | 1,258.50 | |
Average Common Equity |
(133.50) | (232.50) | (215.00) | (218.00) |
Columns are period end dates · fundamentals updated 2 Nov 2026